Breaks Categories: News

WednesdaySep 02, 2026 10:44 am

BioMedNewsBreaks — Earth Science Tech, Inc. (OTC: ETST) Shareholders Approve Uplisting Strategy, Series B Preferred Stock Retirement

Earth Science Tech (OTC: ETST) announced voting results from its first Annual Meeting of Stockholders, held virtually Aug. 31, 2026. Shareholders approved the company pursuit of a reverse stock split, valid for 12 months and to be used only if the board determines it is necessary to meet minimum bid-price requirements for an uplisting to a national securities exchange. Shareholders also authorized the board independent Special Committee to negotiate the retirement of the Series B Preferred Stock, which the company said would eliminate its dual-class, super-voting control structure. Shareholders also approved the company cash-only “Say-on-Pay” executive compensation structure and elected a three-year review cycle, re-elected all seven director nominees and ratified Semple, Marchal…

Continue Reading

MondayAug 31, 2026 12:15 pm

BioMedNewsBreaks – Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) Draws ‘Buy’ Rating on Lucid-MS Potential

Disseminated on behalf of Quantum BioPharma Ltd. and may include paid advertising. Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) received a ‘Buy’ rating from Rodman & Renshaw, which initiated coverage with an $8.00 price target based on the company’s Lucid-MS drug candidate. Described as a potentially first-in-class non-immunomodulatory small molecule, Lucid-MS is being developed to address neurodegeneration and disability progression in progressive multiple sclerosis, an area where therapeutic options remain limited. The firm’s $8.00 price target reflects its valuation of Quantum BioPharma’s development pipeline. For more information on Lucid-MS, visit https://ibn.fm/8uqwL About Quantum BioPharma Ltd. Quantum is a biopharmaceutical company dedicated to building a…

Continue Reading

ThursdayAug 27, 2026 12:00 pm

BioMedNewsBreaks – NeuroOne Medical Technologies Corporation (NASDAQ: NMTC) Completes Three Large-Animal Procedures Using StereoCED(TM) Platform

NeuroOne (NASDAQ: NMTC) reported the successful completion of three large-animal procedures using its next-generation StereoCED(TM) platform as part of an ongoing preclinical epilepsy research program at the University of Minnesota. In two procedures, NeuroOne drug delivery electrodes delivered a study agent directly into targeted brain tissue while also recording intracranial electrophysiological activity from the same regions, a combination the company believes has not previously been demonstrated in convection-enhanced delivery. The procedures were designed to establish technical feasibility and validate the integrated surgical and drug delivery workflow. NeuroOne said the repeatability demonstrated across the three procedures provides additional confidence as it advances toward the planned launch of StereoCED(TM) for human investigational clinical studies later this quarter. Development…

Continue Reading

WednesdayAug 26, 2026 9:00 am

BioMedNewsBreaks – Nanox Imaging Ltd. (NASDAQ: NNOX) to Report Second-Quarter 2026 Financial Results Sept. 9

Nanox (NASDAQ: NNOX), an innovative medical imaging technology company, announced it will report financial results for the quarter ended June 30, 2026, before market open on Sept. 9, 2026. CEO and Acting Chairman Erez Meltzer and CFO Guy Nathanzon will host a conference call beginning at 8:30 a.m. ET to review the results and provide a business update. A live webcast will also be available through the Investor Relations section of the Nanox website. To view the full press release, visit https://ibn.fm/y877D About Nanox Nanox (NASDAQ: NNOX) is focused on driving the world’s transition to preventive health care by delivering…

Continue Reading

MondayAug 24, 2026 12:05 pm

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) and Secarna Report Positive Early Results From Antibody Oligonucleotide Collaboration

VERAXA Biotech (NASDAQ: VRXA) and Secarna Pharmaceuticals GmbH & Co. KG announced initial positive results from their strategic research collaboration to develop next-generation antibody oligonucleotide conjugates (“AOCs”) for autoimmune and chronic immune diseases. In early in vitro studies, an AOC candidate combining the companies’ technologies demonstrated greater potency than the equivalent unconjugated oligonucleotide, supporting the potential of the approach to selectively deliver therapeutic oligonucleotides to disease-specific cells. The companies said they are discussing next steps in the collaboration, which VERAXA noted demonstrates the potential application of its proprietary click chemistry-powered conjugation technology beyond its primary focus on solid tumors. To view the full press release, visit https://ibn.fm/IF9Cy About VERAXA Biotech AG (NASDAQ:…

Continue Reading

FridayAug 21, 2026 3:30 pm

BioMedNewsBreaks – VERAXA Biotech AG (NASDAQ: VRXA) Strengthens Clinical Development Path for Next-Gen Cancer Therapy

VERAXA Biotech (NASDAQ: VRXA) recently received favorable Scientific Advice from Germany’s Paul-Ehrlich-Institute (“PEI”) regarding the development strategy for its lead BiTAC-TCE cancer therapy, providing regulatory guidance on the program’s biological rationale, pharmacokinetics and planned non-clinical safety studies ahead of potential clinical trials. The company views the feedback as an early regulatory validation that could reduce development uncertainty and clarify the path toward the clinic. VERAXA’s lead candidate previously produced encouraging preclinical results presented at the 2026 AACR Annual Meeting, where the company reported selective targeting of cancer cells carrying two biomarkers while sparing cells with only one, potentially improving the…

Continue Reading

ThursdayAug 20, 2026 10:49 am

BioMedNewsBreaks – Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) (WKN: A3EKSZ) Enters LOI for Exclusive Option on LAG-3 Inhibitor Program

This article has been disseminated on behalf of Onco-Innovations Limited and may include paid advertising. Onco-Innovations (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H, WKN: A3EKSZ) entered into a non-binding letter of intent (“LOI”) with Ifowonco Informatics Incorporated as an initial step toward negotiating a definitive agreement that, if completed, would grant Onco an exclusive option relating to Ifowonco’s proprietary small-molecule inhibitor program targeting lymphocyte-activation gene 3 (“LAG-3”). The proposed collaboration is intended to combine Ifowonco’s oral small-molecule immune checkpoint technology with Onco-Innovations’ expertise in DNA damage response (“DDR”) therapeutics, translational oncology and clinical development, with the companies believing the combination of DDR inhibition and LAG-3 blockade could potentially enhance anti-tumour immune responses across multiple solid tumour indications. Ifowonco’s program is…

Continue Reading

WednesdayAug 19, 2026 10:55 am

BioMedNewsBreaks – Earth Science Tech, Inc. (OTC: ETST) Acquires Zoolzy to Expand Pharmaceutical Supply Chain and Veterinary Market Reach

Earth Science Tech (OTC: ETST), a strategic holding company focused on a diversified portfolio, announced the acquisition of Zoolzy LLC, a Doral, Florida-based wholesale distributor of active pharmaceutical ingredients (“APIs”) and finished FDA-approved prescription products. Operating from a 3,684-square-foot facility, Zoolzy is expected to integrate into ETST’s supply chain and enable its compounding pharmacies to procure APIs at competitive wholesale pricing, which the company says could increase overall profit margins. The acquisition also broadens ETST’s access to novel APIs for custom compounding and provides immediate procurement access to common veterinary medications. ETST plans to leverage the new supply line to…

Continue Reading

TuesdayAug 18, 2026 11:18 am

BioMedNewsBreaks – Nanox Imaging Ltd. (NASDAQ: NNOX) Signs Exclusive UK Reseller Agreement for HealthOST AI Bone Solution

Nanox (NASDAQ: NNOX) , a leader in innovative medical imaging technology, announced that subsidiary Nanox AI Ltd. entered into a sales reseller agreement with Vertec Scientific Ltd. for the commercialization of its Nanox.AI bone solution, HealthOST, in the United Kingdom. The agreement grants Vertec an exclusive license to market and resell HealthOST in the UK, subject to minimum annual license commitments, for an initial three-year term. HealthOST is an FDA-cleared and UKCA/CE-marked AI software solution that analyzes eligible routine CT scans to support clinicians in evaluating and assessing musculoskeletal disease of the spine, including osteoporosis. In November 2025, the National Institute for Health and Care Excellence (“NICE”) recommended HealthOST and a previous version, HealthVCF, among five AI technologies for National Health Service (“NHS”)…

Continue Reading

MondayAug 17, 2026 1:55 pm

BioMedNewsBreaks — Dyadic International, Inc. (NASDAQ: DYAI) Entered Agreements for $2.9 Million Registered Direct Offering and Private Placement 

Dyadic International (NASDAQ: DYAI) doing business as Dyadic Applied BioSolutions, entered into definitive agreements with an institutional investor for a registered direct offering of 3,625,000 common shares and a concurrent private placement of warrants to purchase 3,625,000 common shares. The common shares are priced at $0.795 each and the warrants at $0.005 each, with the warrants carrying an exercise price of $0.84 per share. Aggregate gross proceeds are expected to be approximately $2.9 million. The transactions are expected to close on or about Aug. 14, 2026, subject to customary closing conditions. Dyadic intends to use the net proceeds, together with existing cash, cash equivalents,…

Continue Reading